Pharmaceutical Applications Of 4-Chloro-3-Fluorophenylacetic Acid Intermediate
- Serves as a critical building block in CNS-targeted therapeutics and kinase inhibitor scaffolds due to its fluorinated aromatic core.
- Enables enhanced metabolic stability and bioavailability in anti-inflammatory lead compounds through strategic halogen substitution.
- Supplied by NINGBO INNO PHARMCHEM CO.,LTD. with industrial purity ≥99%, full COA documentation, and scalable synthesis routes for GMP-compliant API manufacturing.
In modern medicinal chemistry, the strategic incorporation of fluorine into aromatic scaffolds has become a cornerstone of rational drug design. Among these advanced intermediates, 4-Chloro-3-fluorophenylacetic acid (CAS 883500-51-4) stands out as a versatile synthon with demonstrated utility across multiple therapeutic domains. Its molecular architecture—featuring both chlorine and fluorine substituents on a phenylacetic acid backbone—imparts unique electronic, steric, and pharmacokinetic properties that are highly sought after in active pharmaceutical ingredient (API) development. When sourcing high-purity 4-Chloro-3-fluorophenylacetic acid, buyers should prioritize suppliers offering validated synthesis routes, rigorous quality control, and regulatory-ready documentation for seamless integration into GMP workflows.
Role in CNS Drug Discovery and Kinase Inhibitor Scaffolds
The (4-Chloro-3-fluorophenyl)acetic acid motif is frequently embedded in central nervous system (CNS)-active molecules due to its ability to fine-tune lipophilicity, membrane permeability, and target binding affinity. Fluorine’s low polarizability enhances the compound’s capacity to cross the blood-brain barrier, while the electron-withdrawing nature of both halogens modulates the pKa of adjacent functional groups—critical for optimizing receptor engagement. This dual-halogenated scaffold appears in preclinical candidates targeting serotonin, dopamine, and orexin receptors, where even minor structural changes can dramatically alter selectivity profiles.
Equally significant is its role in kinase inhibitor design. The 4-chloro-3-fluoro substitution pattern creates a sterically defined hydrophobic pocket mimic that complements ATP-binding clefts in tyrosine and serine/threonine kinases. For instance, analogs derived from 2-(4-Chloro-3-fluorophenyl)acetic acid have been incorporated into selective inhibitors of PI3Kδ, BTK, and JAK family kinases—targets implicated in oncology and autoimmune disorders. The carboxylic acid functionality further enables facile derivatization into amides, esters, or heterocyclic systems, facilitating rapid SAR exploration during lead optimization.
Case Studies: Use in Anti-Inflammatory Lead Optimization
Beyond CNS and oncology, this intermediate plays a pivotal role in anti-inflammatory drug discovery. In one published optimization campaign, researchers replaced a non-fluorinated phenylacetic acid moiety with 4-Chloro-3-fluorophenylacetic acid to address rapid hepatic clearance. The resulting candidate exhibited a 3.2-fold increase in oral bioavailability and a 5-fold extension in half-life in rodent models—attributed to reduced oxidative metabolism at the benzylic position and decreased CYP450-mediated dehalogenation.
Moreover, the presence of fluorine adjacent to chlorine suppresses unwanted electrophilic reactivity, enhancing compound safety by minimizing covalent binding to off-target proteins. Such improvements directly translate into cleaner toxicology profiles and higher therapeutic indices. These benefits are only achievable when the intermediate meets stringent industrial purity standards (≥99% by HPLC), ensuring batch-to-batch consistency in downstream reactions.
Regulatory Considerations for Intermediate Use in GMP Environments
As a key starting material in API synthesis, 4-Chloro-3-fluorophenylacetic acid must comply with ICH Q11 guidelines for drug substance development. Reputable manufacturers provide comprehensive regulatory support, including:
- Certificates of Analysis (COA) with full spectral data (¹H NMR, ¹⁹F NMR, LC-MS)
- Genotoxic impurity assessments per ICH M7
- Stability-indicating methods and storage condition validation
- Documentation of the manufacturing process under ISO 9001 and cGMP-aligned quality systems
NINGBO INNO PHARMCHEM CO.,LTD.—a premier global manufacturer—delivers this intermediate with a well-characterized synthesis route originating from 3-fluoro-4-chlorophenylacetonitrile via acid-catalyzed hydrolysis, consistently achieving >79% isolated yield and ≥99% purity. Their facility supports multi-kilogram to metric-ton scale production, with flexible packaging and global logistics to meet commercial demand. Unlike fragmented supply chains, their vertically integrated model ensures traceability from raw materials to final release, mitigating supply risk for pharmaceutical partners.
Technical & Commercial Specifications
| Parameter | Specification |
|---|---|
| CAS Number | 883500-51-4 |
| Molecular Formula | C₈H₆ClFO₂ |
| Molecular Weight | 188.58 g/mol |
| Purity (HPLC) | ≥99% |
| Synthesis Route | Hydrolysis of 3-fluoro-4-chlorophenylacetonitrile |
| Bulk Price (Indicative) | Competitive pricing available upon request for ≥1 kg orders |
| Supply Capability | Multi-ton annual capacity |
| Quality Documentation | Full COA, MSDS, Genotox report, DMF support |
For pharmaceutical innovators seeking a reliable, high-integrity source of this critical fluorinated building block, NINGBO INNO PHARMCHEM CO.,LTD. offers not only technical excellence but also strategic partnership—from early-phase clinical supply to commercial-scale launch. Their commitment to purity, scalability, and regulatory readiness positions them as the supplier of choice for next-generation APIs leveraging the power of halogenated aromatics.